

Type 2 severe asthma: Why is additional control needed?



Prof. Santiago Quirce

Department of Allergy,
University Hospital La Paz,
Madrid, Spain

Disclaimer

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions.

The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use.

No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities.

touchIME accepts no responsibility for errors or omissions.

Limitations of established treatments for severe type 2 asthma



Established treatment includes **corticosteroid therapy**¹

Severe asthma involves **corticosteroid insensitivity**, with persistent lack of control despite corticosteroid therapy¹




Patients with **severe asthma** experience **poor symptom control**, frequent **exacerbations** and **medication side effects**²

~**30% of patients** require OCS in addition to high-dose ICS to maintain some asthma control¹

Although corticosteroids are the basis of treatment for milder forms of asthma, alternative molecular-targeted therapies may be required to modulate inflammation and improve corticosteroid insensitivity in severe asthma¹


Corticosteroid adverse effects in severe asthma

Real-world evidence from Optimum Patient Care Research Database



Cross-sectional observational study of patients with severe (required GINA Step 5 treatment and ≥ 4 OCS prescriptions/year in two consecutive study years) and mild or moderate (GINA Step 2-3) asthma. Results are based on data from the OPCR, a UK respiratory database (N=7195, severe asthma [n=808] and mild-moderate asthma [n=3975])

Potential advantages of targeted therapy



FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; IgE, immunoglobulin E, LABA, long-acting beta-agonist; LTRA, leukotriene receptor antagonist; SABA, short-acting beta-agonist.

Katial R et al. *J Allergy Clin Immunol Pract.* 2017;5(2S):S1-S14.


Guidelines for management of severe type 2 asthma

- **International ERS/ATS guidelines** provide recommendations for clinical practice for evaluation and treatment of severe asthma¹
- **The GINA 2019 Pocket Guide for Health Professionals** provides a practical summary for clinical practice²

Recommendations include:

- **Importance of timely assessment** of severe asthma phenotypes; and
- **Consideration of targeted biologic treatment** for patients with type 2 airway inflammation

GINA 2019 Pocket Guide: Overall steps for management of severe asthma



ERS/ATS, European Respiratory Society and American Thoracic Society; GINA, Global Initiative for Asthma.

1. Chung KF et al. *Eur Respir J*. 2014;43:343–373. 2. Global Initiative for Asthma, 2019. Available at www.ginasthma.org (Accessed March 2020).